Physician profile
John B Gordon
NPI 1962483099
$9,623.58
in general payments reported to CMS, 2019-2025
36 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,021 · 2020: $1,388 · 2021: $1,719 · 2022: $1,622 · 2023: $1,270 · 2024: $423 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,067.06 | 2019-2025 | Xience Skypoint, Aveir, Mitraclip |
| W. L. Gore & Associates, INC. | $1,113.76 | 2019-2024 | Gore Excluder Aaa Endoprosthesis, Gore Excluder Thoracoabdominal Branch Endoprosthesis, C3 Delivery System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,092.05 | 2019-2024 | Lifevest |
| Amgen INC. | $621.53 | 2019-2024 | Repatha |
| Shockwave Medical, INC | $479.73 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $316.98 | 2019-2023 | Ingevity+, Latitude Communicator Power Supply |
| Janssen Pharmaceuticals, INC | $312.98 | 2019-2022 | |
| Medtronic Vascular, INC. | $293.07 | 2019-2020 | |
| Cathworks, INC. | $292.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $278.84 | 2019-2022 | |
| Cvrx, INC. | $196.04 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $160.54 | 2019-2023 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $157.57 | 2020-2021 | |
| Medtronic, INC. | $156.60 | 2021-2022 | |
| Philips North America LLC | $122.64 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $115.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.23 | 2021 | |
| Heartflow, INC. | $112.90 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $100.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $64.12 | 2019-2020 | |
| Ge Healthcare | $60.09 | 2019 | |
| Alnylam Pharmaceuticals INC. | $49.12 | 2019-2022 | |
| Baxter Healthcare | $47.18 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $34.95 | 2020-2023 | |
| Csl Behring | $30.09 | 2019 | |
| Bardy Diagnostics, INC. | $27.00 | 2020-2021 | |
| Akcea Therapeutics, INC. | $26.25 | 2019 | |
| Irhythm Technologies, INC. | $23.40 | 2022 | |
| Astellas Pharma US INC | $23.13 | 2019 | |
| Tactile Systems Technology INC | $22.95 | 2019 | |
| Biosense Webster, INC. | $22.55 | 2021 | |
| Biotronik INC. | $21.59 | 2021 | |
| United Therapeutics Corporation | $19.16 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.78 | 2019 | |
| Sobi, INC | $15.90 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.